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Hepatitis B, hepatitis C, HIV, and VDRL seroprevalence of
blood donors in Mersin, Turkey*
Seva ÖNER, Gülçin YAPICI, Caferi Tayyar ŞAŞMAZ, Ahmet Öner KURT, Resul BUĞDAYCI

Aim: The aim of this study was to determine the seroprevalence and affecting factors of Hepatitis B surface antigen
(HbsAg), hepatitis C virus antibody (anti-HCV), anti human immunodeficiency virus (anti-HIV), and VDRL in blood
donors in Mersin.
Materials and methods: This was a retrospective, descriptive study. All blood centers in Mersin were included in the
study. The medical records of 30,716 blood donors were evaluated. The data were analyzed using descriptive analysis,
linear-by-linear association test, and the Pearson chi-square significance test.
Results: Of the donors, 691 (2.2%) had positive HbsAg, 125 (0.4%) had positive anti-HCV, and 46 (0.1%) had positive
VDRL test. The confirmation test was positive in 1 participant out of 54 (0.2%), whose anti-HIV test was positive. Of
the participants, 862 (2.8%) showed at least 1 positive test result. In one participant, both HbsAg and anti-HCV tests
were positive.
Conclusion: There was at least 1 blood-borne disease seropositivity in 2.8% of the donors. Seroprevalence increased
with age in males.
Key words: Blood donors, HbsAg, anti-HCV, anti-HIV, VDRL

Mersin, Türkiye’de kan donörlerinde hepatitis B, hepatitis C, HIV ve VDRL
seroprevalansı
Amaç: Bu çalışmanın amacı, Mersin’de kan donörlerinde Hepatitis B surface antigen (HbsAg), Hepatitis C virus antibody (anti-HCV), anti Human Immunodeficiency Virus (anti-HIV) ve VDRL seroprevelanslarını ve etkileyen faktörleri
belirlemektir.
Yöntem ve gereç: Bu çalışma retrospektif tanımlayıcı bir çalışmadır. Çalışmaya Mersin’deki tüm kan merkezleri alındı
ve 30716 donörün kayıtları değerlendirildi. Verilerin analizinde tanımlayıcı istatistikler, Linear by linear association test
ve Pearson Ki-kare önemlilik testleri kullanıldı.
Bulgular: Donörlerin 691’inde (% 2,2) HbsAg pozitif, 125’inde (% 0,4) anti-HCV pozitif, 46’sında (% 0,1) VDRL pozitifti. Anti-HIV pozitif olan 54 kişinin (% 0,2) birinde doğrulama testi pozitifti. Araştırmaya alınanların 862’sinde (%
2,8) en az bir tane test pozitifliği vardı. Bir kişide hem HbsAg hemde anti-HCV pozitifti.
Sonuç: Donörlerin % 2,8’inde en az bir kanla bulaşan enfeksiyon seropozitifliği tespit edilmiştir. Seroprevelans
erkeklerde yaşla beraber artmaktadır.
Anahtar sözcükler: Kan donörleri, HbsAg, anti HCV, anti HIV, VDRL
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Introduction
Medical treatment aims at rescuing lives and health
promotion. However, medical treatment methods
may sometimes be directly or indirectly harmful for
the patients and may even cause death (1). One out
of 2 people in the world needs blood transfusion at
least once or more. Some of the clinical conditions
where blood transfusion is necessary are surgical and
traumatic causes, leukemia, thalassemia, hemophilia,
severe anemia, and pregnancy complications. The last
2 are more common causes in developing countries
(2).
World Health Organization (WHO) Global
Database on Blood Safety report for 2000-2001
stated that 500,000 women died during pregnancy
or withing 12 months after delivery. Of these deaths,
25% were due to massive obstetrical bleeding. Road
traffic accidents were the second leading cause for
serious injuries in the 5-29 age group. These causes
increase the need for blood transfusion due to
traumatic reasons (3).
Albeit the vital importance of transfusion,
transfusion related diseases may be life-threatening.
Hepatitis was the first disease related to transfusion
and was first described by Beeson in 1943. Hepatitis
B virus (HBV) antigen was found in 1965, hepatitis A
virus (HAV) was identified in 1973, and hepatitis C
virus (HCV) was found in 1988. In order to prevent
transmission of these diseases by transfusion, Food
and Drug Administration (FDA) of the United
States of America recommends serological tests in
all donors of whole blood and its components for
syphilis, HbsAg, anti-human immunodeficiency
virus (anti-HIV), anti-human T-lymphotropic virus
(HTLV)-1, and anti-HCV, and anti-hepatitis B core
antigen (antiHbc) (4).
WHO estimates that approximately 2 billion
people are infected by HBV in the world and that 350
million are chronic HBV carriers. Each year 4 million
acute clinical cases are seen in the world and 25% of
these become carriers, potential sources of infection.
One million people die every year due to chronic
active hepatitis, cirrhosis, or primary liver carcinoma
(5). WHO estimates that 3% of the world population
has HCV infection. There are 4 million carriers only
in Europe (6).
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It was estimated that there were 2.2 million people
with HIV/AIDS in 52 European countries by the end
of 2005 and of these 1.6 million were living in Eastern
Europe and Middle Asia countries (7). It was estimated
that 45 million new HIV infections would occur by
2010 in the world. If precautions are neglected, more
than 4 million of these infection cases will be caused
by healthcare services (unsafe blood transfusion,
injections, and other interventions) (1). Of HIV
infections in the world, 5%-10% is transmitted by
contaminated blood and blood products (8).
In developed countries, 94% of blood is collected
from non-remunerated volunteers, whereas in the
countries with low or medium income, more than
43% of the donors are remunerated or are family/
replacement donors (3). According to the Turkish
legislation of blood and blood products, which was
put into practice in 1983, it is obligatory to examine
all donated blood for HbsAg, VDRL/RPR, and
malaria. In 1985, anti-HIV and in 1996, anti-HCV
were added to the list. In 1997, malaria was excluded
from the list of screened infections. Today, it is
obligatory to examine all donor blood for HbsAg,
anti-HCV, anti-HIV, and VDRL, and to complete a
donor questionnaire (9).
The aim of this study was to determine the
seroprevalence and the affecting factors for HbsAg,
anti-HCV, anti-HIV, and VDRL in blood donors in
Mersin.
Materials and methods
This study was conducted between November
2006 and February 2008 in Mersin, a southern city
of Turkey in the Mediterranean region. The study
was approved by the Local Ethics Committee and
other official institutions. This investigation was
planned as a retrospective descriptive study based
on official records. Seven centers (Blood Centers
of Mersin University Faculty of Medicine Hospital,
Mersin, Toros, Erdemli, Silifke, and Tarsus State
Hospitals, and Mersin Red Crescent Blood Center)
were included in the study. The donor forms and
serological test results of all donors between January
1, 2006 and December 31, 2006 were assessed.
Evaluation stages of individuals applying for
donation in blood centers:
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Filling out the Donor Query Form: A form inquiring
about the following details is filled by the donors: the
general health of the donor, phobias about needle,
blood, etc., donation history in the last 2 or 3 months,
vaccine, medication, dental interventions, medical
care in the last year, history of chronic diseases, blood
and blood products transfusion in the last year or
organ transplantation, operation, rabies vaccination,
cancer, hematological disease, hemorrhagic diathesis,
hepatitis, tuberculosis, malaria, syphilis, AIDS,
psoriasis, history of acne, drug addiction, history
of risky sexual behavior, tattooing, acupuncture,
history of ear-piercing, receiving growth hormone,
rapid weight loss and history of unexpected disease
findings, abortus, curettage and history of pregnancy
for women. Information is evaluated by a physician.
The donation is then accepted, temporarily rejected,
or permanently rejected. Physical examination
and laboratory analysis of the accepted donors are
performed and recorded onto the donor form.
Donor Record Form: This form includes sociodemographic information, such as city of birth,
age, blood type, address, sex, education, profession,
marital status, being a relative of the patient receiving
the transfusion or a voluntary donor, donation
number, date of the last donation, information of
received blood quantity and type, place of donation:
in a centre or in an ambulatory service, information
of screening test results, reason for not using the
donation (if not used), weight, body temperature,
pulse rate, blood pressure, hemoglobin, hematocrit,
leukocyte, and platelet count, physical examination,
and laboratory findings.
Donor Record Form Evaluation: The donor age
should be between 18 and 65 years. The intervals
between whole blood donations should be at least 2
months.
On physical examination, the donor should be 50
kg or over, body temperature should not be over 37.5
°C, cardiac pulse rate should range between 50 and
100/min; systolic blood pressure should be between
100 mmHg and 180 mmHg. Diastolic blood pressure
should be between 50 mmHg and 100 mmHg.
Injection sites showing intravenous drug addiction
or erythema are investigated. In case these findings
exist and if the donor exhibits narcotic drug or
alcohol intoxication findings, she/he is rejected.

Laboratory: Minimum level for hemoglobin is
12.5 g/dL, and for hematocrit it is 38%. The leukocyte
count should be at between 5000 and 10,000/mm3.
Blood donation is acquired from accepted
individuals and donated blood is tested for HbsAg,
anti-HCV, anti-HIV, and syphilis (VDRL or RPR card
test). Confirmatory test is performed on blood that
is found to be reactive. Blood reactive for anti-HIV
is sent to Refik Saydam Hygiene Centre for Western
Blot confirmation test. If the result is reactive, the
test results are sent to the provincial directorate of
health, while the individual is informed and referred
to the infectious diseases clinic. On confirmation of
other reactive tests, the same serum sample is studied
again using the same method. If the repeated result
is negative, a third test is performed; when the result
comes out to be negative at 2 consecutive tests, the
result is accepted as “negative”. When the repeated
result is reactive again, it is accepted as “reactive”.
Test results are recorded onto serology record forms
along with identity information. Reactive results are
also reported to the provincial directorate of health
and the individual is informed and referred to the
infectious disease clinic.
In our study, donor record forms, sociodemographic details (sex, age, educational,
occupational and marital status, blood group, and
being a volunteer or patient relative), and the number
of donations were recorded onto computer. The
results of HbsAg, anti-HCV, anti-HIV, and VDRL
were recorded using the serological test results
registry. All data of 30,723 donors were installed using
a computer. Seven individuals, whose laboratory
results could not be located, were excluded from the
study. Analysis was performed using the data that
belonged to 30,716 donors.
The classification and definitions used in the
study: With regard to professions of the donors,
housewives, students, and unemployed individuals
are classified as “unemployed”.
Statistical analysis
Data were analyzed using the descriptive analysis,
linear-by-linear association test, and the Pearson chisquare significance test for comparison of variables.
The level of significance was set as P ≤ 0.05.
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Results
Of the 30,716 donors, 29,587 (96.3%) were male,
and 1129 (3.7%) were female. The mean age of the
donors was 34.6 ± 10.0 (min = 18, max = 65); 10,071
(32.8%) were in the 18-29 age group, and 8825
(28.7%) were ≥ 40 years of age. It was observed that
3315 (53.0%) were primary school graduates, 1045
(16.7%) were university graduates, 2817 (74.7%)
were married, 2146 (46.0%) were traders, and 1213
(26.0%) were workers; 548 (8.3%) donated for the
first time, 6060 (91.7%) for second time or more,
7705 (28.8%) were volunteers, and 19,094 (71.2%)
were patient relatives (Table 1).
While 691 (2.2%) donors were tested positive for
HbsAg, 125 (0.4%) tested positive for anti-HCV, and
46 (0.1%) tested positive for VDRL. Of the 54 (0.2%)
participants whose anti-HIV tests were positive, only
1 showed a positive confirmation test. Among the
donors, 862 (2.8%) showed at least 1 positive test
result. In 1 patient, both HbsAg and anti-HCV tests
were positive.
The anti-HCV positivity was higher in
unemployed participants than in other occupational
groups (P < 0.001, χ2 = 26.5).
A positive HbsAg result or any other positive
result was more common in donors in Mersin city
center than in donors of the other towns (P = 0.002,
χ2 = 14.8, P = 0.003, χ2 = 13.9). The probability of
any positive test result increased in men as the age
increased (P = 0.046, linear-by-linear association =
6.2). This trend was not valid for women.
There was no significant relationship between a
positive result for HbsAg, anti-HCV, anti-HIV and
VDRL/RPR tests and age groups, sex, educational
status, marital status, and the number of donations
(Table 2).
Discussion
Majority of the donors (96.3%) were male. This
was 51.5% in the USA, 52.9% in Georgia, 93%
in Jordan, and 91% in Kuwait (10-13). In Turkey,
women are usually housewives and this may lead
them to avoid outdoor activities. Moreover, women
have lower hemoglobin levels and a higher number
of vasovagal reactions. This may cause the high rate
of refusal for women donors.
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Table 1. Demographic characteristics and reason and number
of donations.
Demographic details
Sex (n = 30,716)
Male
Female
Age groups (n = 28,395)
18-29
30-39
≥40
Educational status (n = 6253)
Primary school
High school
University
Marital status (n = 3769)
Married
Single
Occupational status (n = 4664)
Unemployed
Government employee
Worker
Trader
Technician
Number of donations (n = 6608)
The first time
≥2
Reason for donation (n = 26,799)
Volunteer
Patient relative
Region (n = 30,716)
Mersin city centre
Silifke
Tarsus
Erdemli

n

%

29,587
1129

96.3
3.7

10,071
9499
8825

35.5
33.4
31.1

3315
1893
1045

53.0
30.3
16.7

2817
952

74.7
25.3

202
811
1213
2146
292

4.3
17.4
26.0
46.0
6.3

548
6060

8.3
91.7

7705
19,094

28.8
71.2

27,132
1834
999
751

88.3
6.0
3.3
2.4

The HbsAg prevalence was reported as 3.4%
in Georgia, 1.7% in Jordan, 1.1%-3.5% in Kuwait,
2.16% in Pakistan, and 2.1% in Achaia in southwest
Greece (11-15). The WHO declared that Turkey is an
intermediate (2%-7%) endemic region for hepatitis B
carriers (6). In a national study, Emekdas et al. found
that HbsAg positivity was 4.19% (2.4-11.5%) in
6,240,130 donors in 22 blood centers between 1996
and 2004 (16). In other regional studies, this rate
was found to be 2.5%-8.7%, while it was 2.4%-9.1%
in community-based studies (17-27). Our results are
consistent with these studies.
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Table 2. Distribution of positive test results by independent variables.
HBSAg

Anti HCV

VDRL

Any positive
test result

n

%**

n

%**

n

%**

n

%**

665

2.2

122

0.4

46

0.2

833

2.8

26

2.3

3

0.3

0

0.0

29

2.6

Sex
Male

n = 29,587

Female

n = 1129

Age groups
18-29

n = 10,071

208

2.1

40

0.4

9

0.1

257

2.6

30-39

n = 9499

208

2.2

37

0.4

19

0.2

264

2.8

≥40

n = 8825

224

2.5

34

0.4

16

0.2

275

3.1

73

2.2

8

0.2

6

0.2

87

2.6

Educational status
Primary school n = 3315
High school

n = 1893

34

1.8

4

0.2

3

0.2

41

2.2

University

n = 1045

17

1.6

4

0.4

1

0.1

22

2.1

Married

n = 2817

57

2.0

9

0.3

5

0.2

71

2.5

Single

n = 952

24

2.5

4

0.4

0

0.0

28

2.9

4

2.0

4

2.0*

0

0.0

8

4.0

Government employee n = 811

11

1.4

3

0.4

2

0.2

16

2.0

Worker

n = 1213

26

2.1

2

0.2

2

0.2

30

2.5

Trader

n = 2146

42

2.0

2

0.1

5

0.2

49

2.3

Technician

n = 292

3

1.0

1

0.3

0

0.0

4

1.4

8

1.5

1

0.2

0

0.0

9

1.6

160

2.6

21

0.3

3

0.0

185

3.1

Marital status

Occupational status
Unemployed* n = 202

Number of donations
The first time

n = 548

≥2 .

n = 6060

Reason for donation
Volunteer

n = 7705

Patient relative n = 19,094

199

2.6

27

0.4

3

0.0

230

3.0

404

2.1

78

0.4

36

0.2

517

2.7

642

2.4*

115

0.4

39

0.1

796

2.9*

Region
Mersin city centre* n = 27,132
Tarsus

n = 1834

27

1.5

4

0.2

2

0.1

33

1.8

Silifke

n = 999

11

1.1

4

0.4

3

0.3

18

1.8

Erdemli

n = 751

11

1.5

2

0.3

2

0.3

15

2.0

*P < 0.05 **: Percent of row

We found that HbsAg or any other positive results
were higher in donors in the Mersin city centre than
those donors in other towns. In a national field study,
HbsAg positivity was found as 2.6% in rural and
2.85% in urban regions (23), which is in line with the
findings of the current study.

The major risk factor for Hepatitis C is parenteral
exposure, primarily due to blood products and needle
sharing in drug addicts. The WHO has stated antiHCV positivity as 0.3%-0.5% in volunteer donors
in the USA. The Far East, the Mediterranean, Africa
and the East European countries are regions with
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high prevalence of anti-HCV. It has been reported
that 20% of blood donors in Egypt have anti-HCV
positivity. This figure is over 5% in some communities
in Italy, 6.9% in Georgia, 4.2% in Pakistan, 2.1% in
Kuwait, and 0.5% in Greece (7,11,13-15). Turkey is a
low endemic region for HCV. Anti-HCV positivity
is lower than HBsAg positivity. Emekdas et al. found
anti-HCV positivity as 0.41% (0.21%-0.95%) (16).
In Turkey, anti-HCV prevalence was determined
to be 0.02%-5.2% in donor studies, whereas it was
0.02%-2.6% in field studies (17-21,24,26,28). We
found higher anti-HCV positivity in unemployed
individuals than in other occupational groups.
This result may be coincidental as the number of
participants with occupational data was very few.
The prevalence for syphilis was 2.4% in donors in
Georgia, and 0.75% in Pakistan (11,14). In Turkey,
the prevalence of syphilis was determined as 0.02% in
Kocaeli, 0.31% in Çanakkale, and 0.47% in Trabzon
provinces (17-19). There was no positive result in a
study in Mersin (20). We found VDRL test positivity
as 0.1% in our study.
Anti-HIV positivity was found in 3 out of 4970
donors in Georgia, in 1 out of 26,874 donors in
Kuwait, in 0.004% in Pakistan, and in 6.2 in 100,000
person-years in Canada (11,13,14,29). In national
studies, anti-HIV prevalence was found to be quite
low. In a study in Trabzon, 20 donors out of 33,766
donors had suspected anti-HIV, 3 out of 5350 donors
in Afyon, and 8 out of 29,049 donors in Kocaeli had
anti-HIV positivity; however, they gave negative test
results in the confirmation tests (17,19,21). There was
no anti-HIV positive donor in a study in Çanakkale
(18). A previous study in Mersin revealed that 0.13%
of the donors had anti-HIV positivity and negative
results for anti-HIV confirmation test (20). In our
study, 0.2% had anti-HIV positivity, and 1 donor
showed a positive result in the anti-HIV confirmation
test. Our results were consistent with other national
studies.
Previous studies found that the incidence of
blood-transmitted infections was 2 or 3 times higher
in first-time donors than multi-time donors (29,30).
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We found no correlation between the number of
blood donation and the prevalence of blood-borne
disease.
Gogos et al. found higher infection rates in males
than females (15). In Turkey, Altındis et al. did not
find a sex difference (26). In our study, there were
no significant differences in the results for HbsAg,
anti-HCV, anti-HIV and VDRL/RPR tests by gender.
However, positive test results were higher as the age
increased in males. This trend was not observed in
females. The reason for this may be the exposure to
risks being more common in males.
WHO recommend that voluntary, unremunerated blood donors from low risk population
are selected for blood donation. Family/replacement
and paid blood donation are associated with higher
prevalence of transfusion-transmitted infections (8).
However, family/replacement blood donors systems
are applied in many countries. It was reported that
84.7% of donations in Kuwait were for the purpose
of replacement, and 15.3% of donors were volunteers
(13). In Pakistan, 99% of donors were patient relatives
or friends (14). In our study, 71.2% of donors were
patient relatives and 28.8% were volunteers.
We believe that the community should be
educated regarding the prevention from blood-borne
and sexually transmitted diseases, and voluntary
donation should be promoted by active studies in
order to attenuate transfusion-related infections.
Nevertheless, since women are in the low risk group,
we think that it would be beneficial to include women
in these studies intensively.
The limitation of our study is due to lack of
information in the donor query forms, some variables
could only be evaluated in limited numbers.
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